A safety evaluation of dimethyl fumarate in moderate-to-severe psoriasis

References

• Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52(1):23–26.
   PubMed Web of Science ®Google Scholar
• Richard MA, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the « OBJECTIFS PEAU » study. J Eur Acad Dermatol Venereol. 2018;32(11):1967–1971.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–392.
   PubMed Web of Science ®Google Scholar
• Shah K, Mellars L, Changolkar A, et al. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017;77(2):287–292.e4.
   PubMed Web of Science ®Google Scholar
• Havnaer A, Weinberg JM, Han G. Systemic therapies in psoriasis: an update on newly approved and pipeline biologics and oral treatments. Cutis. 2019;104(2S):17–20.
   PubMedGoogle Scholar
• Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med. 2005;11(1):43–48.
   PubMed Web of Science ®Google Scholar
• Lijnen R, Otters E, Balak D, et al. Long-term safety and effectiveness of high-dose dimethylfumarate in the treatment of moderate to severe psoriasis: a prospective single-blinded follow-up study. J Dermatolog Treat. 2016;27(1):31–36.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Szepietowski JC, Loewe R, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® - and placebo-controlled trial (BRIDGE). Br J Dermatol. 2017;176(3):615–623.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PCM, Loewe R, Mrowietz U, et al. Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study. J Eur Acad Dermatol Venereol. 2020;34(1):119–126.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Barker J, Boehncke WH, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018;32(Suppl 3):3–14.
   PubMedGoogle Scholar
• Gieselbach RJ, Muller-Hansma AH, Wijburg MT, et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol. 2017;264(6):1155–1164.
   PubMed Web of Science ®Google Scholar
• Balak DM. Fumaric acid esters in the management of psoriasis. Psoriasis (Auckl). 2015;5:9–23.
   PubMedGoogle Scholar
• Das J. The role of mitochondrial respiration in physiological and evolutionary adaptation. Bioessays. 2006;28(9):890–901.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol. 1999;141(3):424–429.
   PubMed Web of Science ®Google Scholar
• Skilarence. European Medicines Agency. Available from: https://www.ema.europa.eu/en/documents/product-information/skilarence-epar-product-information_en.pdf
   Google Scholar
• Aubets J, Jansat JM, Salva M, et al. No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P‐glycoprotein (P‐gp) drug transporter. Pharmacol Res Perspect. 2019;7(6). DOI:10.1002/prp2.540
   PubMed Web of Science ®Google Scholar
• Nibbering PH, Thio B, Zomerdijk TP, et al. Effects of monomethylfumarate on human granulocytes. J Invest Dermatol. 1993;101(1):37–42.
   PubMed Web of Science ®Google Scholar
• Thio HB, Zomerdijk TP, Oudshoorn C, et al. Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes. Br J Dermatol. 1994;131(6):856–861.
   PubMed Web of Science ®Google Scholar
• Sebök B, Bonnekoh B, Mahrle G. IL-1 alpha-induced expression of ICAM-1 on cultured hyperproliferative keratinocytes: suppression by antipsoriatic dimethyl-fumarate. Int J Dermatol. 1994;33(5):367–370.
   PubMed Web of Science ®Google Scholar
• Sebok B, Bonnekoh B, Vetter R, et al. The antipsoriatic dimethyl-fumarate suppresses interferon-gamma -induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique. Eur J Dermatol. 1998;8(1):29–32.
   PubMed Web of Science ®Google Scholar
• Vandermeeren M, Janssens S, Borgers M, et al. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun. 1997;234(1):19–23.
   PubMed Web of Science ®Google Scholar
• de Jong R, Bezemer AC, Zomerdijk TP, et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996;26(9):2067–2074.
   PubMed Web of Science ®Google Scholar
• Asadullah K, Schmid H, Friedrich M, et al. Influence of monomethylfumarate on monocytic cytokine formation–explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res. 1997 Oct;289(11):623–630.
   PubMed Web of Science ®Google Scholar
• Ockenfels HM, Schultewolter T, Ockenfels G, et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol. 1998;139(3):390–395.
   PubMed Web of Science ®Google Scholar
• Stoof TJ, Flier J, Sampat S, et al. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol. 2001;144(6):1114–1120.
   PubMed Web of Science ®Google Scholar
• Treumer F, Zhu K, Gläser R, et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121(6):1383–1388.
   PubMed Web of Science ®Google Scholar
• Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol. 2001;116(2):203–208.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Shakery K, Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol. 2007;156(5):838–842.
   PubMed Web of Science ®Google Scholar
• Rostami-Yazdi M, Clement B, Schmidt TJ, et al. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol. 2009;129(1):231–234.
   PubMed Web of Science ®Google Scholar
• Höxtermann S, Nüchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology. 1998;196(2):223–230.
   PubMed Web of Science ®Google Scholar
• Sondermann W, Rompoti N, Leister L, et al. Lymphopenia and CD4+/CD8+ cell reduction under Fumaric acid esters. Dermatology. 2017;233(4):295–302.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Bae JH, Kang SG, et al. Pro-oxidant status and Nrf2 levels in psoriasis vulgaris skin tissues and dimethyl fumarate-treated HaCaT cells. Arch Pharm Res. 2017;40(9):1105–1116.
   PubMed Web of Science ®Google Scholar
• Kornberg MD, Bhargava P, Kim PM, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;360(6387):449–453.
   PubMed Web of Science ®Google Scholar
• Zhao G, Liu Y, Fang J, et al. Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1α (HIF-1α). Biochem Biophys Res Commun. 2014;448(3):303–307.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Seo HA, Go Y, et al. Dimethylfumarate suppresses adipogenic differentiation in 3T3-L1 preadipocytes through inhibition of STAT3 activity. PLoS One. 2013;8(4):e61411.
   PubMed Web of Science ®Google Scholar
• Kaluzki I, Hailemariam-Jahn T, Doll M, et al. Dimethylfumarate inhibits colorectal carcinoma cell proliferation: evidence for cell cycle arrest, apoptosis and autophagy. Cells. 2019;8(11). pii: E1329.
   PubMed Web of Science ®Google Scholar
• Nugteren-Huying WM, van der Schroeff JG, Hermans J, et al. Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 1990;22(2 Pt 1):311–312.
   PubMed Web of Science ®Google Scholar
• Altmeyer PJ, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol. 1994;30(6):977–981.
   PubMed Web of Science ®Google Scholar
• Nieboer C, de Hoop D, van Loenen AC, et al. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol. 1989;20(4):601–608.
   PubMed Web of Science ®Google Scholar
• Nieboer C, de Hoop D, Langendijk PN, et al. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica. 1990;181(1):33–37.
   PubMedGoogle Scholar
• Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol. 1992;27(5 Pt 1):769–771.
   PubMed Web of Science ®Google Scholar
• Sticherling M, Mrowietz U, Augustin M, et al. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol. 2017;177(4):1024–1032.
   PubMed Web of Science ®Google Scholar
• Reich K, Augustin M, Thaçi D, et al. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br J Dermatol. 2019. DOI:10.1111/bjd.18384
   Web of Science ®Google Scholar
• Thaҫi D, Pinter A, Sebastian M, et al. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment: results from a randomised, active comparator-controlled phase 3b trial (POLARIS). Br J Dermatol. 2019. DOI:10.1111/bjd.18696
   PubMed Web of Science ®Google Scholar
• Inzinger M, Weger W, Heschl B, et al. Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions. J Eur Acad Dermatol Venereol. 2013;27(7):861–866.
   PubMed Web of Science ®Google Scholar
• Ismail N, Collins P, Rogers S, et al. Drug survival of fumaric acid esters for psoriasis: a retrospective study. Br J Dermatol. 2014;171(2):397–402.
   PubMed Web of Science ®Google Scholar
• Falkvoll S, Gerdes S, Mrowietz U. Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: results of a prospective study. J Dtsch Dermatol Ges. 2019;17(9):906–912.
   Google Scholar
• Balak DM, Fallah-Arani S, Venema CM, et al. Addition of an oral histamine antagonist to reduce adverse events associated with fumaric acid esters in the treatment of psoriasis: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015;172(3):754–759.
   PubMed Web of Science ®Google Scholar
• O’Gorman J, Russell HK, Li J, et al. Effect of Aspirin pretreatment or slow dose titration on flushing and gastrointestinal events in healthy volunteers receiving delayed-release dimethyl fumarate. Clin Ther. 2015;37(7):1402–1419.e5.
   PubMed Web of Science ®Google Scholar
• Reich K, Hartl C, Gambichler T, et al. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study). J Dtsch Dermatol Ges. 2016;14(1):50–58.
   PubMed Web of Science ®Google Scholar
• Tzaneva S, Geroldinger A, Trattner H, et al. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study. Br J Dermatol. 2018;178(3):682–688.
   PubMed Web of Science ®Google Scholar